(ADMP) Market Cap $33 million--Cash $17 M --FDA Decision on Oct.31 for ZIMHI a treatment of opioid overdose which is a large market --company has already one marketed drug for the treatment of anaphylaxis launched early this year and partnered with Sandoz(Novartis) targeting a $1.5 BILLION Market .Current valuation of $33million is a PURE GIFT for this company a potential 10 bagger here . STRONG BUY SUPER AGGRESSIVE Admamis Pharma (ADMP) Market-Cap:$33 million Cash: $17 million Price: $0.54 Presentation http://ir.adamispharmaceuticals.com/static-files/63eff6dd-0286-457e-a959-920540f0cdb1 ZIMHI (naloxone) injection Indication–Opioid Overdose Addressable Market -$330 million FDA action date Oct. 31, 2019 SYMJEPI (epinephrine) injection Indication-Anaphylaxis Addressable Market -$1.5 billion Launched–January 2019 First products using patented, FDA-approved injection device Both doses (0.3mg and 0.15mg) are FDA approved Sandoz a division of Novartis –commercial partner in U.S. Commercial deal terms –50% of net profits, upfront fee and potential performance-based milestone payments Exploring potential licensing options for ex-US territories Near-Term Target Milestones FDA action date (PDUFA) of Oct. 31, 2019 on NDA for ZIMHI Pursuing potential partnerships for SYMJEPI (ex-US) and ZIMHI product candidate Continued launch of SYMJEPI in U.S. –retail and SYMJEPI low dose launches pending Largest Shareholders : Heights Capital...3.0M 683 Capital ...2.4M The Vanguard ...1.8M First Manhattan...1.4M BlackRock...952.8K Morgan Stanley...625.7K Geode Capital...337.2K Carlo (Dennis J)...292.3K Moss (Ronald B)...285.0K GSA Capital...139.6K
CHEAPEST FDA GEM ..FDA DECISION next Week guys (ADMP) Price: $0.55 / Mkt-Cap $34 M / Cash $17 M / FDA Decision on OCTOBER 31 treatment of Opioid Overdose .. A MEGA drug which is targeting a $1.5 BILLION Market was launched early this year with partner Novartis . https://www.rttnews.com/slideshow/3...a-rare-genetic-disorder-cancers.aspx?Slide=16
ADMP= PARTNERDEAL imminent according to management read below ..market cap of $33 million is a big joke for this company could go to over $100 million valuation on good news https://finance.yahoo.com/news/adamis-pharmaceuticals-announces-second-quarter-203000698.html ZIMHI (naloxone) Injection On March 14, 2019, Adamis announced that the FDA had accepted the company’s New Drug Application (NDA) for review and provided a target agency action date (PDUFA) of October 31, 2019. The company believes that if approved, ZIMHI could be an important part of the solution to this growing health crisis of opioid overdose. The company is in discussions with several potential partners for ZIMHI with the goal of finalizing a commercial distribution agreement for the U.S. prior to a potential approval.
